What Conner Mantz said about breaking the American half-marathon record — and being left with some regrets
"I’m more just mad at myself for getting too caught up in the record and not caught up enough in the sprint finish," the ...
Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a ...
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations ...
Hosted on MSN24d
D. Boral Capital Upgrades Citius Pharmaceuticals (CTXR)
Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. Analyst Price Forecast Suggests 121.74% Upside As of ...
Yahoo Finance24d
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an ...
Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25
Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the ...
Citius Oncology’s Strategic Positioning and Lymphir’s Market Launch Drive Buy Rating
In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Oncology (CTOR – Research Report), with a ...
Former BYU runner shatters American half-marathon record
“For the second consecutive year, Weini Kelati improved on the American record at the Houston Half Marathon,“ Runner’s World ...
Nasdaq26d
Citius Pharma Reports 2024 Financial Results and Business Update
Citius Pharma ( (CTXR)) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pharmaceuticals, Inc. is a biopharmaceutical company ...
Benzinga.com25d
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Quotes, Forecast and News Summary
Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million registered direct offering. US Stock Futures Slip After Friday's Fall ...
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the ...
Seeking Alpha28d
CTOR Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed ...